ライフサイエンスコーパス: transplantation

1 going total pancreatectomy (autologous islet transplantation).

2 ssue compared with lungs undergoing standard transplantation.

3 as to quantify the risk of SCI in pancreatic transplantation.

4 in situ and ex situ model of rat donor liver transplantation.

5 eatment strategy for infants undergoing lung transplantation.

6 PB were performed at least 1 year after transplantation.

7 with a reduced incidence of AKI after liver transplantation.

8 as an unavoidable consequence of solid organ transplantation.

9 drug use, radiation therapy, and solid organ transplantation.

10 munosuppressive drugs for use in solid organ transplantation.

11 to 1.3 x 1010 donor mononuclear cells before transplantation.

12 d, he proceeded to simultaneous liver-kidney transplantation.

13 o confer survival advantage after intestinal transplantation.

14 ne in the setting of hematopoietic stem cell transplantation.

15 rs for GVHD development following intestinal transplantation.

16 ce and increased HSC activity in bone marrow transplantation.

17 ts at several timepoints up to 3 years after transplantation.

18 otherapy and the distribution of cells after transplantation.

19 ped, help revitalize the field of intestinal transplantation.

20 n other pathological conditions beyond organ transplantation.

21 the early 2000s followed by blood stem cell transplantation.

22 n can expand the therapeutic window for hNSC transplantation.

23 nitiation of maintenance dialysis, or kidney transplantation.

24 ifferent times during organ preservation and transplantation.

25 etected only in the minor antigen-mismatched transplantation.

26 gimen that can be applied to allogeneic cell transplantation.

27 al applications in cellular- and organ-level transplantation.

28 lude surgical resection, ablation, and liver transplantation.

29 gnosis, and future plans for chemotherapy or transplantation.

30 Most (93%) had undergone renal or liver transplantation.

31 nuation of immunosuppression following liver transplantation.

32 e to refer an affected individual for kidney transplantation.

33 at risk of ESRD should be identified before transplantation.

34 graft outcomes in experimental and clinical transplantation.

35 f ischemia-reperfusion injury in solid organ transplantation.

36 the forefront of innovation in modern liver transplantation.

37 e risk of complications still exists despite transplantation.

38 patients after allogeneic hematopoietic cell transplantation.

39 f a dnDSA, 65.3 months (median) after kidney transplantation.

40 specific IgE or IgG responses 24 months post-transplantation.

41 ce cross-dressing following liver and kidney transplantation.

42 of transmission of SARS-CoV-2 through organ transplantation.

43 ith grafts functioning at least 1 year after transplantation.

44 CD50 kidney that was eventually accepted for transplantation.

45 lution to improve equity in access to kidney transplantation.

46 s to assess the suitability of the organ for transplantation.

47 ue has gained interest in the field of organ transplantation.

48 sensorimotor (cylinder) test is reversed by transplantation.

49 ed for precise selection of HCC patients for transplantation.

50 cal outcomes, particularly surrounding liver transplantation.

51 timation of myocardial performance following transplantation.

52 nt prolongation of liver preservation before transplantation.

53 ryonic kidney 293 (HEK293) cells, and hAFSCs transplantation.

54 cts enrolled in the Clinical Trials in Organ Transplantation-09 study in which we randomized stable k

55 m-cell allograft, and 1 death was related to transplantation (4%).

56 For each transplantation, a stratum was created that matched one

57 ic syndrome is allogeneic hematopoietic cell transplantation, a therapy unavailable to many patients

58 r overcoming two major issues in human islet transplantation: (a) poor yield of islets from donated p

59 a from the adult-to-adult living donor liver transplantation (A2ALL) study, which represents the larg

60 evidence of reduction in organ donation and transplantation activity across the world.

61 Kingdom and resumption of living donor liver transplantation activity in India toward the end of the

62 Compared with offering only intestinal transplantation, adding teduglutide cost ${\$}$124,353/Q

63 acute rejection (BCAR) within 60 weeks after transplantation; adverse event coding was centralised.

64 ortality after allogeneic hematopoietic cell transplantation (allo-HCT).

65 zation of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is limited by GVHD.

66 kemia (AML) who undergo allogeneic stem cell transplantation (alloSCT), and carries a grave prognosis

67 s, with or without autologous haematopoietic transplantation and a plethora of new agents, the progre

68 equires expertise in both living donor liver transplantation and advanced laparoscopic liver surgery.

69 Manipulation of the gut microbiome by transplantation and cohousing demonstrated that transfer

70 munocompromised zebrafish for xenograft cell transplantation and credentials the model as a new precl

71 HLA antibodies pose a significant barrier to transplantation and current strategies to reduce allosen

72 nt the first reported experience with kidney transplantation and donation in transgender patients.

73 nses in a variety of models, including organ transplantation and graft versus host disease (GVHD) but

74 Our findings inform organ transplantation and hepatic immunotherapy, revealing rem

75 ur patient underwent hematopoietic stem cell transplantation and is well 8 years later.

76 rejection and allograft loss in solid organ transplantation and may act synergistically with HLA don

77 Hematopoietic stem cell transplantation and NF-kappaB1 pathway-targeted therapeu

78 Liver transplantation and PSC-related events accounted for app

79 to be considered when assessing patients for transplantation and treatment posttransplantation.

80 We enrolled patients who underwent kidney transplantation and were actively followed up in two hos

81 d received high-dose melphalan and stem cell transplantation and/or treatment with a proteasome inhib

82 ed from donor-recipient pairs at the time of transplantation, and from recipients at several timepoin

83 studied in AREG(-/-) mice after bone marrow transplantation, and in mice with myeloid cell-specific

84 in the busulfan group received treatment and transplantation, and in the treosulfan group 221 receive

85 cohort of patients with heart failure, heart transplantation, and left ventricular assist device.

86 lignancy, allogeneic hematopoietic stem cell transplantation, and neutropenia were not.

87 lowed by autologous haematopoietic stem cell transplantation, and prospective trials have demonstrate

88 quantity and quality of the organ supply for transplantation are desired.

89 ancies or undergoing hematopoietic stem cell transplantation are vulnerable to colonization and infec

90 le highlighting the potential of interneuron transplantation as an autism therapy.

91 se report of simultaneous liver and pancreas transplantation as treatment of WRS in a small child in

92 ed the incorporation of autologous stem cell transplantation (ASCT) into a carfilzomib-lenalidomide-d

93 Autologous stem cell transplantation (ASCT) is a standard of care in eligible

94 nfused after a standard autologous stem cell transplantation (ASCT).

95 enitors and rebalanced HSC lineage output in transplantation assays.

96 ese recommendations, the American Society of Transplantation (AST) facilitated a consensus workshop t

97 In 2017, the American Society of Transplantation (AST) launched the Outstanding Questions

98 mother had died of the disease, proceeded to transplantation at age 49 with a 12/12 human leukocyte a

99 eir home institution versus those who sought transplantation at an alternative institution (55.3% ver

100 Upon transplantation, atypical neurofibromas generated geneti

101 gens in the context of peripheral tolerance, transplantation, autoimmune diseases and cancer.

102 ion in a man, 8 years after his first facial transplantation because of extensive disfigurement from

103 n therapy for presumed HCC followed by liver transplantation between January 2011 and December 2015 a

104 s, who were referred and evaluated for liver transplantation between January and June 2012 were studi

105 lts (age >=18) who underwent first-time lung transplantation between March 2018 (when united network

106 t advances in adult stem cell enrichment and transplantation, bioengineering, and gene transfer have

107 ic malignancies treated with blood or marrow transplantation (BMT) and that inclusion of these SNPs i

108 in a Cynomolgus macaque model of bone marrow transplantation (BMT) for tolerance induction.

109 rodents using human neural stem cell (hNSC) transplantation, but the procedure is invasive, requires

110 5% CI -50.4, -8.5, p<0.006), and referral to transplantation by 115.1 days (95% CI -179.5, -50.7, p<0

111 ronment delayed hematopoietic recovery after transplantation by decreasing endothelial proliferation

112 novel means to perform VSP and virtual face transplantation by interacting with and manipulating pat

113 These findings demonstrate that interneuron transplantation can exert therapeutic behavioral effects

114 Although cell transplantation can rescue motor defects in Parkinson's

115 Mortality risk after kidney transplantation can vary significantly during the post-t

116 (SRTR) data to identify 92 081 adult kidney transplantation candidates who were offered a DCD50 kidn

117 4) donor kidneys subjected to CI followed by transplantation (CI+Txp).

118 els were history of haematopoietic stem-cell transplantation, cumulative alkylating drug dose, and an

119 Analysis of clinical transplantation data linked low circulating levels of GD

120 The success of allogeneic hematopoietic cell transplantation depends heavily on the delicate balance

121 and transplant center levels to ensure safe transplantation despite significant redirection of resou

122 Irradiation and bone marrow transplantation did not further affect body weight, bloo

123 l and sex disparities in living donor kidney transplantation do not appear to be related to network s

124 To identify changes to organ donation and transplantation during this time, an anonymous web-based

125 testing capacity can support continued organ transplantation, even in a SARS-CoV-2 hyperendemic area.

126 Bacterial community transplantation experiments demonstrated a causal role o

127 Bone marrow transplantation experiments identify hematopoietic cells

128 Moreover, in utero transplantation experiments suggested that the rostrocau

129 Organ recovery for transplantation fell by 17% (P = .0001) with a further 1

130 e safety and feasibility of fecal microbiota transplantation (FMT) and reinduction of anti-PD-1 immun

131 to properly evaluate the candidate to liver transplantation for alcoholic liver diseases and severe

132 ased assessment of patients undergoing heart transplantation for early risk stratification, patient m

133 oing chemotherapy or hematopoietic stem cell transplantation for hematological malignancy at St.

134 deceased donor kidneys but reduces access to transplantation for older patients and results in greate

135 afness that requires hematopoietic stem cell transplantation for survival.

136 e curative effect of hematopoietic stem cell transplantation for the hematopoietic features of SMARCD

137 The endpoints were rebleeding and rebleeding/transplantation-free survival for 4 years.

138 712 patients with CGD who underwent allo-HCT transplantation from March 1993 through December 2018.

139 ILD referred or on the waiting list for lung transplantation from May 2013 to December 2017 underwent

140 Additionally, gut microbiota transplantation from MIA mice produced behavioral defici

141 ite International Society for Heart and Lung Transplantation guidelines, a significant proportion ind

142 Bone marrow stem cell transplantation had not been accessible during her child

143 otherapy and subsequent autologous stem-cell transplantation, had an Eastern Cooperative Oncology Gro

144 Liver transplantation has been increasingly reported over the

145 reconstitution after hematopoietic stem cell transplantation has been observed, we hypothesized that

146 Allergy transfer upon solid organ transplantation has been reported in the literature, alt

147 igation of these processes in clinical organ transplantation has, however, been hampered by the lack

148 who are ineligible for autologous stem-cell transplantation have poor outcomes and few treatment opt

149 ite of death/ventricular assist device/heart transplantation (hazard ratio, 0.85 [95% CI, 0.76-0.94];

150 higher risk of nonarrhythmic death or heart transplantation (hazard ratio, 11.01 [95% CI, 2.96-40.95

151 Post hematopoietic cell transplantation (HCT) autoimmune cytopenia (AIC) is a po

152 ies undergoing allogeneic hematopoietic cell transplantation (HCT) for difficult-to-control infection

153 Hematopoietic cell transplantation (HCT) is the primary curative approach,

154 Hematopoietic cell transplantation (HCT) remains the only curative treatmen

155 reventing acute GvHD post hematopoietic cell transplantation (HCT), its efficacy and long-term outcom

156 Hematopoietic stem cell transplantation (HSCT) improves clinical outcomes in KD

157 I) before allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with acute

158 tion post allogeneic hematopoietic stem cell transplantation (HSCT).

159 Heterotopic tracheal transplantation (HTT) mouse model was used to evaluate t

160 g immunosuppression such as, diabetes, organ transplantation, Human immunodeficiency virus (HIV) infe

161 associated side effects preclude intestinal transplantation if motivated only by an expectation of i

162 has enabled incompatible living donor kidney transplantation (ILDKT) across HLA/ABO barriers, but add

163 (cPRA) are associated with increased kidney transplantation in 100% cPRA patients.

164 rmone levels both in serum and saliva during transplantation in 7 postmenopausal female patients with

165 logy, visual outcome and survival of corneal transplantation in children and to identify the risk fac

166 tudy was to compare the preparation time for transplantation in children of different weights and to

167 potential for immunological rejection after transplantation in humans.

168 ecretagogues, and elevate blood glucose upon transplantation in mice.

169 ysis, adjusted risk of death 12 months after transplantation in recipients with a kidney from donors

170 patients should be considered for intestinal transplantation in the event of progressive intestinal f

171 of ageing, sex, the gut microbiome and organ transplantation in this complex interplay are also discu

172 of acute liver failure (ALF) requiring liver transplantation in USA and its frequency is increasing i

173 Additional indications for transplantation include large desmoid tumors and other i

174 In organ transplantation, infection and rejection are major cause

175 SC self-renewal defect is rescued after cell transplantation into a normal microenvironment, thus pro

176 port mature T cell development in vivo after transplantation into humanised immunodeficient mice.

177 sence of an effective treatment, direct cell transplantation into the CNS to restore myelin has been

178 stress and subtype defects are alleviated by transplantation into the mouse cortex.

179 Islet transplantation is a promising treatment for T1D, but lo

180 Salvage liver transplantation is an efficient treatment of recurrences

181 Islet transplantation is an emerging therapy for type 1 diabet

182 ent, prognosis remains poor, and double-lung transplantation is an option for eligible patients.

183 ll, the 1-year survival rate following liver transplantation is lower than that seen in patients who

184 Organ transplantation is often lifesaving, but the long-term d

185 Hematopoietic stem cell transplantation is the only curative option, but a high

186 ing and patient risk stratification in renal transplantation is the single antigen bead (SAB) assay.

187 liver is the primary site for clinical islet transplantation, it poses several restrictions, especial

188 Intestinal transplantation (ITx) can be life-saving for patients wi

189 Temporary ileostomy during intestinal transplantation (ITx) is the standard technique for allo

190 d-stage renal disease is longer after kidney transplantation (KT) compared with those remaining on di

191 clinical rejection (SCR) screening in kidney transplantation (KT) using protocol biopsies and noninva

192 erstand the impact of the epidemic on kidney transplantation (KT), at both the national and center le

193 s remain a major threat to successful kidney transplantation (KT).

194 tudied outcomes following living donor liver transplantation (LDLT) post-PVTT downstaging (DS) with s

195 robust microvasculature in lung grafts after transplantation, leading to better posttransplant outcom

196 an increasingly common indication for liver transplantation (LT) in the United States and in many pa

197 o combat the geographic disparities in liver transplantation (LT) rates.

198 omic signature in the first week after liver transplantation (LT) that is associated with graft loss

199 paucity of data on the outcome of DCD liver transplantation (LT) utilizing livers with macrosteatosi

200 llular carcinoma (HCC) recurring after liver transplantation (LT) when HCC is unsuitable for surgical

201 atocellular carcinoma (HCC) listed for liver transplantation (LT).

202 of monitoring allograft function after lung transplantation (LT).

203 day mortality of patients referred for liver transplantation (LT).

204 sociated with mortality while awaiting liver transplantation (LT).

205 lop chronic kidney disease (CKD) after liver transplantation (LT).

206 ficant regional variations in COVID-19, lung transplantation (LTx) remains a critical life-saving ope

207 these results suggest that fecal microbiota transplantation may be a treatment option in sepsis asso

208 Zebrafish are an ideal cell transplantation model.

209 -term skin allograft survival in a stringent transplantation model.

210 r inhibition efficacy using in vivo MMTV-neu transplantation mouse model.

211 Liver transplantation (n = 17) normalized B(T) and eliminated

212 In 2018, the Organ Procurement and Transplantation Network (OPTN) modified adult heart allo

213 were identified in the Organ Procurement and Transplantation Network/United Network for Organ Sharing

214 virus (HIV)/AIDS, cancer, stem cell or organ transplantation, nonsteroid immunosuppressive therapy, i

215 er trial demonstrated safety and efficacy of transplantation of 30 HCV-viremic kidneys into HCV-negat

216 Following transplantation of a latently infected organ, reactivati

217 Here, we determined that transplantation of BAT (+BAT) improves cardiac function

218 To replace the lost cells, the transplantation of DA neurons derived from embryonic ste

219 The results revealed that transplantation of fecal microbiota from schizophrenic p

220 B-cell lymphoblastic leukemia and underwent transplantation of hematopoietic stem cells from his hum

221 Transplantation of mesenchymal stem cells/multipotent st

222 Transplantation of microbiota from feces of mice fed the

223 Transplantation of PCs pretransfected with adeno-associa

224 Transplantation of SA-PDL1-engineered islet grafts with

225 ies to TKO pig cells in OWMs complicates the transplantation of TKO pig kidneys in OWMs.

226 The transplantation of vOrganoids into the mouse S1 cortex r

227 Encapsulated beta cell transplantation offers a potential cure for a subset of

228 PV samples from IRI+ orthotopic liver transplantation (OLT) patients (n = 35) decreased activa

229 tion in patients undergoing orthotopic liver transplantation (OLT).

230 ade on the impact of hematopoietic stem cell transplantation on allergy transfer or cure of the disea

231 tment with either a healthy fecal microbiota transplantation or defined commensal bacterial taxa can

232 Eight men and 8 women (28%) underwent heart transplantation or received an LV assist device.

233 rgery (OR, 0.31; 95% CI, 0.30-0.32), corneal transplantation (OR, 0.39; 95% CI, 0.31-0.49), and retin

234 th type 1 diabetes mellitus (allogenic islet transplantation), or the prevention of surgical diabetes

235 matologic neoplasm, after hematopoietic cell transplantation, or as a result of germline testing for

236 ained by exposure to chemotherapy, stem-cell transplantation, or rituximab, except for IRRs for humor

237 occurs as a result of traumatic injury, cell transplantation, or tumor growth, among many others.

238 idence of EBV reactivation and its impact on transplantation outcomes in 71 patients undergoing haplo

239 ole of patient socioeconomic status (SES) in transplantation outcomes is poorly understood because of

240 djusted probability of deceased donor kidney transplantation persist under KAS, even between centers

241 comorbidities, dialysis vintage, and kidney transplantation, PH was associated with twice the 5-year

242 sponders at LVAD implantation (pre-LVAD) and transplantation (post-LVAD).

243 The absence of B cells at the time of transplantation prolonged skin graft survival.

244 poietic reconstitution following bone marrow transplantation provide a window of opportunity whereby

245 els were weakly correlated with CI following transplantation (r = -0.495; P = 0.043).

246 w microenvironment degradation caused by pre-transplantation radiation treatment.

247 er peripheral blood stem cell or bone marrow transplantation, rarely occurs in kidney and pancreas tr

248 d gene expression analyses revealed that VAT transplantation recapitulated the effects of obesity on

249 Cibinetide reduced the initial transplantation-related severe inflammation and delayed

250 ogical approaches are ineffective, and liver transplantation represents the only curative option.

251 (AST) launched the Outstanding Questions in Transplantation Research forum to stimulate a community-

252 rate during the second and fifth weeks after transplantation, respectively.

253 e increasing reports of combined heart-liver transplantation resulting from advanced liver disease, i

254 iplines (hematology, nephrology, obstetrics, transplantation, rheumatology, and neurology), and (d) t

255 bodies (DSA) and poorer outcomes after renal transplantation (RTx).

256 Frailty Heart Workgroup (American Society of Transplantation's Thoracic and Critical Care Community o

257 f the Arm, Shoulder, and Hand; Carroll; Hand Transplantation Score System; Short Form-36; and Kapandj

258 In the presence of 2 factors or more upfront transplantation should be probably preferred to resectio

259 poral region (i.e., the location of HuCNS-SC transplantation) showed a significantly slower progressi

260 unosuppression for simultaneous liver/kidney transplantation (SLKT).

261 Split liver transplantation (SLT) is 1 strategy for maximizing the n

262 ly excluding patients with prior solid organ transplantation (SOT) and posttransplant lymphoprolifera

263 n modulation of HSC activity and bone marrow transplantation studies.

264 elay graft destruction in future human islet transplantation studies.

265 DGF is a relevant problem after kidney transplantation; sufficient microperfusion of the allogr

266 autologous and allogeneic haemopoietic cell transplantation suggest that HIV status does not adverse

267 he authors demonstrated that, following skin transplantation, the donor mast cell-mediated senescence

268 In transplantation, the ever-increasing number of an organ'

269 itled "Evidence-Based Treatment Decisions in Transplantation: The Right Dose & Regimen for the Right

270 iption factor TWIST1 for an efficacious cell transplantation therapy to induce neovascularization-med

271 We review recent advances in bridge-to-transplantation therapy, including the use of a paracorp

272 For transplantation to be effective, grafted neurons should

273 trials in autoimmunity and heart and kidney transplantation to determine effectiveness of inhibiting

274 The median time from transplantation to diagnosis was 10.5 years (0.58-36).

275 irs and patients undergoing fecal microbiota transplantation to evaluate the patterns of acquisition,

276 nhuman leukocyte antigen (HLA) after cardiac transplantation to identify antibodies associated with a

277 We developed a program to offer liver transplantation to selected patients with HCC outside of

278 we employ a sensitized murine model of islet transplantation to test strategies that promote long-ter

279 tolerant alloreactive B cells contribute to transplantation tolerance by foregoing germinal center r

280 infection on: (a) disruption of established transplantation tolerance during tolerance maintenance;

281 Here we used an allogeneic murine islet transplantation tolerance model to examine the impact of

282 den of nosocomial Pneumocystis infections in transplantation units in France was evaluated through a

283 Follow-up occurred from transplantation until development of obesity, last follo

284 fter explantation survival free from LVAD or transplantation was 90% at 1-year and 77% at 2 and 3 yea

285 ity, LV assist device implantation, or heart transplantation was assessed.

286 After multivariate adjustment, en bloc transplantation was associated with superior patient sur

287 Probability of transplantation was correlated in the post-KAS cohort wi

288 The risk of SCI in pancreas transplantation was estimated using the number of radiol

289 yndrome treated with hematopoietic stem cell transplantation was referred for decreased vision relate

290 hazard model, HLA class II antibodies before transplantation were associated with increased adjusted

291 170 consecutive patients evaluated for liver transplantation were taking NSBB.

292 patic decompensation, or liver-related death/transplantation) were assessed, using Cox regression ana

293 n invaluable resource in kidney and pancreas transplantation when vascular reconstruction is needed a

294 ndings could improve graft survival after SL transplantation, which would encourage programs to opt i

295 ificantly (p = 0.026) elevated at day + 7 of transplantation, while salivary progesterone increased a

296 Many children who have undergone solid organ transplantation will require additional support in medic

297 lied in AD+ mice: (i) ACE10/GFP+ bone marrow transplantation with head shielding; and (ii) adoptive t

298 mes in 71 patients undergoing haploidentical transplantation with posttransplantation cyclophosphamid

299 astomosis within the first 3 days after lung transplantation, with more numerous and complex lymphati

300 e percentage of patients referred for kidney transplantation within 1 year of dialysis at the 690 dia